FY2018 EPS Estimates for Audentes Therapeutics Inc Decreased by Leerink Swann (NASDAQ:BOLD)

Audentes Therapeutics Inc (NASDAQ:BOLD) – Equities research analysts at Leerink Swann decreased their FY2018 EPS estimates for Audentes Therapeutics in a research report issued on Tuesday, November 6th, Zacks Investment Research reports. Leerink Swann analyst J. Schwartz now expects that the biotechnology company will earn ($3.44) per share for the year, down from their prior estimate of ($3.41). Leerink Swann also issued estimates for Audentes Therapeutics’ Q4 2018 earnings at ($0.87) EPS, Q1 2019 earnings at ($0.93) EPS, Q2 2019 earnings at ($0.94) EPS, Q3 2019 earnings at ($0.99) EPS, Q4 2019 earnings at ($1.04) EPS, FY2019 earnings at ($3.90) EPS and FY2020 earnings at ($4.02) EPS.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.88) by ($0.09). During the same period last year, the business posted ($0.88) earnings per share.

Other equities analysts also recently issued reports about the company. BidaskClub upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, September 18th. HC Wainwright set a $40.00 target price on shares of Audentes Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 22nd. Mizuho reissued a “buy” rating and issued a $45.00 target price on shares of Audentes Therapeutics in a report on Wednesday, August 22nd. Finally, William Blair reissued a “buy” rating on shares of Audentes Therapeutics in a report on Tuesday, August 7th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. Audentes Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $35.49.

NASDAQ:BOLD traded up $0.64 during mid-day trading on Friday, reaching $25.09. The stock had a trading volume of 747,900 shares, compared to its average volume of 451,596. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -7.38 and a beta of 1.91. Audentes Therapeutics has a 1-year low of $19.62 and a 1-year high of $46.18.

In other news, VP Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $36.88, for a total transaction of $368,800.00. Following the sale, the vice president now owns 100 shares of the company’s stock, valued at $3,688. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Louis G. Lange sold 24,000 shares of Audentes Therapeutics stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $22.49, for a total value of $539,760.00. Following the sale, the director now directly owns 345,799 shares in the company, valued at approximately $7,777,019.51. The disclosure for this sale can be found here. Insiders sold 101,039 shares of company stock worth $3,465,020 in the last three months. 6.60% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. raised its holdings in shares of Audentes Therapeutics by 48.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 67,660 shares of the biotechnology company’s stock valued at $2,586,000 after buying an additional 22,063 shares during the last quarter. MetLife Investment Advisors LLC raised its holdings in shares of Audentes Therapeutics by 89.0% during the second quarter. MetLife Investment Advisors LLC now owns 14,989 shares of the biotechnology company’s stock valued at $573,000 after buying an additional 7,059 shares during the last quarter. California Public Employees Retirement System raised its holdings in shares of Audentes Therapeutics by 311.6% during the second quarter. California Public Employees Retirement System now owns 44,057 shares of the biotechnology company’s stock valued at $1,683,000 after buying an additional 33,352 shares during the last quarter. UBS Group AG raised its holdings in shares of Audentes Therapeutics by 471.9% during the first quarter. UBS Group AG now owns 50,532 shares of the biotechnology company’s stock valued at $1,518,000 after buying an additional 41,696 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Audentes Therapeutics by 25.4% during the second quarter. BlackRock Inc. now owns 2,458,171 shares of the biotechnology company’s stock valued at $93,925,000 after buying an additional 497,767 shares during the last quarter. 84.48% of the stock is currently owned by institutional investors.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: How to invest in a bear market

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply